Venture capital raised: $58.5 million
Respicardia raised $58.5 million in venture capital in its early and later stages of development during the fourth quarter of 2017, according to the MoneyTree Report. This is the company’s eighth investment sequence. One of the investors is ZOLL Medical.
Respicardia is creating implantable therapies that can improve respiratory and cardiovascular health. The company’s Remede System is an implantable stimulation device that restores a regular breathing pattern during sleep for central sleep apnea patients.